



# Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

**Giuseppe M.C. Rosano<sup>1,2\*</sup>, Juan Tamargo<sup>3</sup>, Keld P. Kjeldsen<sup>4,5,6</sup>, Mitja Lainscak<sup>7</sup>, Stefan Agewall<sup>8,9</sup>, Stefan D. Anker<sup>10,11</sup>, Claudio Ceconi<sup>12</sup>, Andrew J.S. Coats<sup>1</sup>, Heinz Drexel<sup>13,14,15</sup>, Gerasimos Filippatos<sup>16</sup>, Juan Carlos Kaski<sup>1</sup>, Lars Lund<sup>17</sup>, Alexander Niessner<sup>18</sup>, Piotr Ponikowski<sup>19</sup>, Gianluigi Savarese<sup>17</sup>, Thomas A. Schmidt<sup>20,21</sup>, Petar Seferovic<sup>22</sup>, Sven Wassmann<sup>23,24</sup>, Thomas Walther<sup>25,26</sup>, and Basil S. Lewis<sup>27,28</sup>**

<sup>1</sup>Department of Medical Sciences, IRCCS San Raffaele, via di val Cannuta, Roma, Italy; <sup>2</sup>Cardiology Clinical Academic Group, St George's Hospitals NHS Trust University of London, Cranmer Terrace, London, UK; <sup>3</sup>Department of Pharmacology, School of Medicine, University Complutense, CIBERCV, 28040 Madrid, Spain; <sup>4</sup>Department of Medicine, Copenhagen University Hospital (Holbæk Hospital), Holbæk, Denmark; <sup>5</sup>Institute for Clinical Medicine, Copenhagen University, Blegdamsvej 3B, 2200 Copenhagen N, Denmark; <sup>6</sup>Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7 D2 DK-9220 Aalborg East, Denmark; <sup>7</sup>Faculty of Medicine, University of Ljubljana; <sup>8</sup>Department of Internal Medicine, General Hospital Murska Sobota, Slovenia; <sup>9</sup>Oslo University Hospital, Oslo universitetssykehus HF, Postboks 4950 Nydalen, 0424 Oslo, Ullevål, Norway; <sup>10</sup>Institute of Clinical Sciences, University of Oslo, Oslo universitetssykehus HF, Postboks 4950 Nydalen, 0424 Oslo, Norway; <sup>11</sup>Division of Cardiology and Metabolism, Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Germany; <sup>12</sup>Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany; <sup>13</sup>University Hospital of Ferrara, U.O. Cardiologia Via Savonarola, 9, 44121 Ferrara FE, Italy; <sup>14</sup>Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria; <sup>15</sup>University of the Principality of Liechtenstein, Triesen, Liechtenstein; <sup>16</sup>National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, 75 Mikras Asias str., 11527 Goudi, Athens, Greece; <sup>17</sup>Karolinska Institutet, and Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden; <sup>18</sup>Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria; <sup>19</sup>Department of Heart Diseases, Wrocław Medical University, Centre for Heart Diseases, Military Hospital, Wrocław, Poland; <sup>20</sup>Department of Emergency Medicine, Holbaek Hospital, University of Copenhagen, Holbæk, Denmark; <sup>21</sup>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; <sup>22</sup>Department of Cardiology, University of Belgrade, Studentski trg 1, 11000 Belgrade, Serbia; <sup>23</sup>Cardiology Pasing, Munich, Germany; <sup>24</sup>University of the Saarland, Homburg/Saar, Germany; <sup>25</sup>Department of Pharmacology and Therapeutics, School of Medicine and School of Pharmacy, University College Cork, Cork, Ireland; <sup>26</sup>Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, Greifswald, Germany; <sup>27</sup>Lady Davis Carmel Medical Center, Mikhel St 7, Haifa 3436212, Israel; and <sup>28</sup>Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, 1 Efron St. Bat Galim, Haifa 3525433, Israel

Received 14 February 2018; revised 11 April 2018; editorial decision 13 April 2018; accepted 26 April 2018; online publish-ahead-of-print 3 May 2018

Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. Renin angiotensin aldosterone system inhibitor therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ~50% of these patients experience two or

\* Corresponding author. Tel +44 (0)2087252763, Email: [grosano@sgul.ac.uk](mailto:grosano@sgul.ac.uk)

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

more yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their therapy down-titrated or more often discontinued even after a single episode of elevated potassium ( $K^+$ ) level. Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease steps should, when hyperkalaemia develops, be considered to lower  $K^+$  level and enable patients to continue their RAASi therapy. The use of such measures are especially important in those patients with the most to gain from RAASi therapy.

## Keywords

Potassium • Hyperkalaemia • Renin angiotensin aldosterone inhibitors • Mineralocorticoid  
• Mineralocorticoid antagonist • Heart failure • Arterial hypertension • Chronic kidney disease

Potassium ( $K^+$ ) is the most abundant cation in the body (50–75 mEq/L/kg body weight). Under physiological conditions, approximately 98% of total body  $K^+$  is located in the intracellular space and only 2% in the extracellular space. Hyperkalaemia defined as serum or plasma  $K^+ > 5$  mmol/L (for  $K^+ 1$  mmol/L = 1 mEq/L) is a common electrolyte disorder that may develop due to increased  $K^+$  intake, reduced  $K^+$  excretion and shift of  $K^+$  from intracellular to extracellular space.

Food is the primary source of  $K^+$  intake with the relative amounts of  $K^+$  differing greatly between foods. The highest amounts of  $K^+$  are found in fruits, vegetables, and meat. However, a sometimes overlooked dietary  $K^+$  source comes from salt substitutes (i.e.  $Na^+$  chloride substituted by  $K^+$  chloride) and nutritional supplements. High  $K^+$  intake may cause hyperkalaemia if renal  $K^+$  excretion is impaired.

The kidneys are, under normal conditions, responsible for up to 90–95% of  $K^+$  elimination with the colon being responsible for the majority of the remaining  $K^+$  excretion. However, the colonic excretion of  $K^+$  increases when renal function worsens. In fact, in patients with end-stage renal disease faecal  $K^+$  secretion is three-fold greater as compared to patients with normal renal function. This finding suggests that the colon might assume an accessory  $K^+$  excretory role and a modest compensatory mechanism for reduced renal  $K^+$  excretion. While long-term regulation of  $K^+$  levels occurs mainly in kidneys, short-term regulation mainly occurs in skeletal muscles.

Several common clinical conditions and drugs (Table 1) are known to cause or aggravate hyperkalaemia. Amongst these drugs, Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are those most frequently associated with hyperkalaemia in patients with cardiovascular disease, but against this must be counter-balanced with the fact that they are among the drugs that confer the most significant survival benefit in patients with cardiovascular disease.<sup>1–8</sup>

Guidance on how best to direct the management of cardiovascular patients in the sub-acute (post-emergency) and chronic phases of hyperkalaemia is in increasing demand due to the increasing use of RAASi. This document is an expert consensus on the optimum management of hyperkalaemia in the post-emergency phase in patients with cardiovascular disease, especially in those receiving or having a compelling indication to receive RAASi.

## Hyperkalaemia

$K^+$  levels were traditionally measured in serum from coagulated blood but are now more often measured in plasma from heparinized blood. Serum levels may be up to 1/2 mEq/L higher than plasma levels. This is especially the case for high values. In addition, errors

associated with blood sampling may also cause erroneously high  $K^+$  levels. These factors must be taken into consideration by the clinician, and must be clarified in any scientific study on hyperkalaemia. In the present document, we mostly use the expression  $K^+$  level since it is unclear in many studies, what was actually measured.

The severity of hyperkalaemia can be classified as mild ( $>5.0$  to  $<5.5$  mEq/L) to moderate (5.5 to 6.0 mEq/L) and to severe at thresholds ( $>6.0$  mEq/L) (Figure 1). The risk for the development of arrhythmic emergencies and sudden arrhythmic death in patients with hyperkalaemia is widely variable as life-threatening arrhythmias may occur at different thresholds and vary between different patients. Often  $K^+$  levels up to 6 mEq/L are found in patients without any signs of arrhythmia, especially if they have chronic kidney disease, diabetes, or heart failure (HF). In these patients, hyperkalaemia is often incidentally discovered whilst performing routine blood tests. Besides, the definition based on  $K^+$  levels, hyperkalaemia can be classified as acute or chronic or recurrent according to the onset and the number of hyperkalaemia episodes experienced. Chronic or recurrent hyperkalaemia is defined as  $K^+$  levels  $> 5$  mEq/L repetitively measured over a 1-year period. Pseudo-hyperkalaemia refers to high  $K^+$  level in the test tube without hyperkalaemia in the body. This may be caused by release of K from blood or tissue during sampling. If pseudo-hyperkalaemia is suspected measurement should be repeated with blood sampled appropriately or eventually taken as an arterial sample. In case of haemolysis, the clinician should consider whether it occurs in the test tube or in the body.<sup>6–10</sup>

The occurrence of hyperkalaemia differs between in- and outpatients. It is present in 2–4% of the general population and in 10–55% of patients hospitalized for any cause depending on the  $K^+$  level used to define hyperkalaemia in the different studies. Both the prevalence of hyperkalaemia and risk of recurrence increase as severity and number of comorbidities increase.<sup>11–28</sup> The incidence of hyperkalaemia increases with the severity of renal impairment, it is often iatrogenic, caused by concurrent drugs and nutritional/herbal supplements (Table 1). In clinical practice, hyperkalaemia occurs in up to 73% of patients with advanced chronic kidney disease and in up to 40% of patients with chronic HF. It leads to more frequent hospitalizations and increased mortality, especially when stringent monitoring is not performed.<sup>3,5,11–35</sup>

Hyperkalaemia frequently occurs in patients with cardiovascular diseases (e.g. HF, arterial hypertension, and coronary artery disease), in particular when combined with renal function impairment, diabetes, and advanced age. Hyperkalaemia may be responsible for cardiac arrhythmias leading to cardiac arrest and death, with a resulting

**Table 1** Drugs/substances that may cause hyperkalaemia

1. Decreased potassium excretion:
  - a. Potassium-sparing diuretics (e.g. spironolactone, triamterene, amiloride)
  - b. Beta-blockers
  - c. NSAIDs
  - d. Sacubitril/valsartan
  - e. Renin-angiotensin-aldosterone inhibitors (RAASi): ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists
  - f. Direct renin inhibitors (aliskiren)
  - g. Mannitol
  - h. Cyclosporine or tacrolimus
  - i. Pentamidine
  - j. Trimethoprim-sulfamethoxazole
  - k. Heparin
  - l. Digitalis
  - m. Calcineurin inhibitors
  - n. Penicillin G
2. Increased potassium intake/administration
  - a. Potassium supplements
  - b. Salt substitute (e.g. DASH)
  - c. Fruits (bananas, melons, orange juice)
  - d. Alfalfa
  - e. Amino acids (aminocaproic acid, arginine, lysine)
  - f. Dandelion
  - g. Dried toad skin
  - h. Hawthorne berry
  - i. Horsetail
  - j. Lily of the valley
  - k. Milkweed
  - l. Nettle
  - m. Noni juice
  - n. Siberian ginseng
  - o. Stored blood products

NSAIDs, non-steroidal anti-inflammatory drugs; ACE, angiotensin converting enzyme; DASH, dietary approach to stop hypertension.

mortality rate of up to 30%. Severe hyperkalaemia is an independent predictor of all-cause and in-hospital mortality and hospitalizations.

Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium carbonate and hyperosmolar sodium (if the individual has hyponatraemia) to stabilize the myocardial cell membrane; insulin w/wo glucose and/or beta adrenoceptor agonists (e.g. salbutamol) (off-label use in some EU countries) and sodium bicarbonate to transfer  $K^+$  into the cells.<sup>17,22,30,36</sup> However, insulin salbutamol, and bicarbonate do not increase  $K^+$  excretion and only provide temporary benefit (1–4 h). Thus, rebound hyperkalaemia can occur after 2 h. This suggests that treatment with a  $K^+$  lowering agent should be initiated as early as possible. Loop diuretics and potassium binders [mainly sodium polystyrene sulfonate (SPS), calcium polystyrene sulfonate (CPS) or patiromer sorbitex calcium (PSC) (Veltassa®), or sodium zirconium cyclosilicate (SZC) or (ZS-9)] can be used to


promote the excretion via renal or gastrointestinal route, respectively.  $K^+$  increasing medicine should be stopped and  $K^+$  intake via food, drinks etc. should be reduced to a minimum. If these measures are ineffective, haemodialysis may be needed (Table 2).

Despite being recommended for use, RAASi drugs are unfortunately seldom re-instated following an episode of hyperkalaemia at or after discharge even if a different clear precipitating cause of hyperkalaemia was detected and eliminated. The most common clinical scenario is that doses of RAASi are reduced, or they are simply discontinued; this is particularly true for mineralocorticoid receptor antagonists (MRAs). Although RAASi dose reduction or discontinuation may reduce the risk of reoccurrence of hyperkalaemia, discontinuation of RAASi is associated with an increased risk of worsening of the underlying cardiovascular condition and mortality.<sup>13,14,37–39</sup>

## Renin angiotensin aldosterone system inhibitors and hyperkalaemia

Renin angiotensin aldosterone system inhibitors are the cornerstone of the treatment of patients with cardiovascular diseases [heart failure with reduced ejection fraction (HFrEF), arterial hypertension, coronary artery disease, myocardial infarction, left ventricular (LV) hypertrophy], with a Class IA recommendation in current clinical guidelines due to the proven reduction of mortality and morbidity in HFrEF.<sup>16,20,40</sup> Renin angiotensin aldosterone system inhibitors are the basis of the treatment of arterial hypertension and in hypertensive patients an MRA must be implemented before resistant hypertension is diagnosed.<sup>15</sup> Renin angiotensin aldosterone system inhibitors are also indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease where they have a specific indication because of the overwhelming evidence of benefit.<sup>15,17</sup>

Since RAASi increase  $K^+$  levels, RAASi-induced hyperkalaemia often limits the use of these drugs thereby offsetting their survival benefits. In hypertensive patients without risk factors for hyperkalaemia, the incidence of hyperkalaemia with RAASi monotherapy is  $\leq 2\%$  and increases to  $\sim 5\%$  with dual RAAS inhibition and to 5–10% when dual therapy is administered in patients with HF or chronic kidney disease.<sup>14,31</sup> According to current guidelines MRAs should be implemented in therapy after an ACEi (or an angiotensin II receptor blocker (ARB) in intolerant patients) has been already initiated.<sup>15–17</sup> In patients with chronic HFrEF, in New York Heart Association (NYHA) functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR  $> 30$  mL/min/1.73 m<sup>2</sup> and  $K^+$  level  $< 5.0$  mmol/L, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalaemia or worsening renal function.<sup>13</sup> Furthermore, in the RALES trial, the benefit of spironolactone was maintained in the setting of moderate hyperkalaemia, and clinical outcomes with spironolactone were superior to placebo when  $K^+$  levels remained  $< 6.0$  mEq/L.<sup>41</sup> In this trial, 13.5% and 40% of participants exhibited hyperkalaemia when treated with 25 and 50 mg daily of spironolactone. This finding suggests that limiting the maximum dose to 25 mg daily may reduce the risk of hyperkalaemia and argues against automatic



**Figure 1** Definitions of normo-kalaemia, hyperkalaemia, and hypokalaemia. Hyperkalaemia can be classified as mild, moderate, or severe. Thresholds for the definition of the severity of hyperkalaemia differ between different classifications. This may mainly be due to different methods used to determine  $K^+$  levels.

**Table 2** Treatment of acute or chronic hyperkalaemia

|  |   |
|--|---|
| Promote uptake of $K^+$ into the intracellular space | Stimulate $Na^+/K^+-ATPase$ : <ul style="list-style-type: none"> <li>• <math>\beta_2</math>-adrenergic agonists (IV, nebulized)</li> <li>• Insulin (IV) <math>\pm</math> glucose</li> <li>• Sodium bicarbonate (if metabolic acidosis)</li> <li>• Combination cocktails</li> </ul>  |
| Cardiac membrane stabilization                       | <ul style="list-style-type: none"> <li>• Calcium chloride or gluconate (IV)</li> <li>• Hypertonic saline (3–5%)</li> </ul>  |
| Increase $K^+$ elimination                           | <ul style="list-style-type: none"> <li>• Loop diuretics (IV, oral) to increase renal <math>K^+</math> excretion</li> <li>• Haemodialysis for removal of <math>K^+</math> from blood</li> <li>• Cation-exchange resins (sodium polystyrene sulfonate) to enhance faecal <math>K^+</math> excretion (PO, PR)</li> <li>• Sodium bicarbonate alkalinizes the urine and increases urinary <math>K^+</math> excretion</li> <li>• New <math>K^+</math> binders: patiromer, sodium zirconium cyclosilicate</li> </ul> |
| Other  | <ul style="list-style-type: none"> <li>• Fludrocortisone (PO) in aldosterone deficiency</li> </ul>  |

IV, intravenous; PO, per os (orally); PR, per rectum; Na, sodium; K, potassium; IV, intravenous; PO, per os.

discontinuation of MRAs when  $K^+$  levels rise  $>5.0$  mmol/L. Indeed, the clinical benefit of spironolactone and eplerenone remained even in those who developed modest elevations in  $K^+$  level in the RALES and EMPHASIS-HF trials.<sup>14,38,39</sup> Up to one-third of NYHA Class II–IV HF patients starting an MRA develop hyperkalaemia ( $>5.0$  mEq/L) over 2 years.<sup>14,42,43</sup>

Patients with cardiovascular disease and chronic kidney disease are at risk of hyperkalaemia and  $\sim 50\%$  of these patients have two or more recurrences within 1 year.<sup>42–45</sup> Incidence rates of hyperkalaemia have been shown to be higher in HFrEF patients on MRA in the

real-world setting than in clinical trials (6–12%), i.e. when they are administered to higher-risk and unselected populations which did not receive  $K^+$  level and/or creatinine monitoring.<sup>44–47</sup> In the real-world setting, the incidence of hyperkalaemia can be as high as 50% in unselected population of patients receiving RAASi.<sup>32,34</sup> Despite this evidence and guideline recommendations,  $K^+$  levels are frequently under-monitored in patients treated with RAASi.<sup>35,48</sup> Therefore, quality improvement programmes are needed to improve rates of laboratory monitoring for patients initiated on MRA therapy, particularly in high-risk patients.

## Hyperkalaemia and discontinuation of Renin angiotensin aldosterone system inhibitors

Hyperkalaemia or borderline high  $K^+$  levels are, together with symptomatic hypotension and worsening renal function, the main reasons that result in discontinuation, dose reduction, or even non-initiation of RAASi therapy in patients with renal and cardiovascular diseases offsetting the survival benefits conferred by these drugs.

A substantial proportion of HF patients are facing a RAASi dose adjustment even after a single instance of elevated serum  $K^+$  levels. According to the European Society of Cardiology Heart Failure Long-Term Registry recruiting 12 440 patients with HFrEF, RAASi were used in 92.2% and 67.0% of patients, respectively.<sup>48</sup> Less than one-third of patients were on guideline-recommended target doses (29.3% for ACEi, 24.1% for ARB, and 30.5% for MRA). In about a third of the patients not achieving the target dosages, a clear reason was not reported (28.8% for ACEi, 29.3% for ARB, and 46.9% for MRA). Hyperkalaemia was the reason for non-use of ACEi/ARB and MRA in 8.5% and 35.1% of patients, respectively.<sup>48</sup>

Among patients with chronic kidney disease RAASi were prescribed at the target guideline recommended dose in 19% to 26% of patients, at submaximal dose in 58% to 65% of patients and were discontinued during follow-up in 14% to 16% of patients.<sup>49</sup> Cardio-renal adverse events/mortality and mortality occurred in 34.3% and 11.0% of patients who discontinued RAASi inhibitors, 24.9% and 8.2% of patients on submaximal doses, and 24.9% and 4.1% of patients on maximum doses, respectively.<sup>49</sup>

Recently, the BIOSTAT-CHF reported that only 22% of patients with HFrEF achieved the recommended treatment dose for ACEi/ARB.<sup>50</sup> Reaching <50% of the recommended dose of ACEi/ARB doses was associated with an increased risk of death and/or HF hospitalization compared with patients reaching  $\geq 100\%$ .<sup>50</sup>

The importance of guideline adherence on prognosis has been recently highlighted by the QUALIFY global survey in 7092 patients with HFrEF.<sup>51</sup> In this registry good adherence to guidelines was associated with a significant prognostic benefit, the adherence score was good in 67%, moderate in 25%, and poor in 8% of patients and the proportion of patients at target dose and at  $\geq 50\%$  of target dose was 27.9% and 63.3% for ACEi and 6.9% and 39.5% for ARBs, respectively.<sup>51</sup>

Despite the fact that data from registries usually provide a more accurate picture than clinical trials regarding on 'real life' situations. Clinical trials, with the latter showing consistently show better treatment results or adherence to interventions. However, even registries they can also identify populations that are receiving better care compared to the general population. Indeed, a recent comparison of patients enrolled and those not enrolled in the Swedish Heart Failure Registry showed that survival was substantially higher in the registry setting, and this was most likely due to better use of RAASi drugs in registry included patients.<sup>52</sup>

**Table 3** Existing recommendations on renin angiotensin aldosterone system inhibitors use according to  $K^+$  levels

| $K^+$ levels | Recommendation   |
|--------------|--|
| >6           | Stop RAASi (ESC HF, <sup>20</sup> NICE <sup>7</sup> )  |
| >5.5 mEq/L   | Reduce dose of/stop ACEi/ARB (K/DOQI <sup>55-57</sup> )  |
| 5.1-5.5      | K/DOQI (e): take measures to lower $K^+$ when initiating RAASi   |
| >5           | Do not start RAASi if >5.0 (K/DOQI, <sup>55-57</sup> HFSA HF, <sup>63</sup> NICE <sup>7</sup> )  |
|              | Reduce dose of/stop RAASi if >5.0 (ACCF/AHA HF, <sup>18</sup> ESC HF, <sup>20</sup> K/DOQI <sup>55-57</sup> )  |
|              | MRA not recommended if >5.0 (HFSA HF <sup>63</sup> )   |
|              | Maintain MRA between 4.0 and 5.0 (ACA/AHA <sup>18</sup> )  |
|              | Do not routinely offer a RAASi to people with CKD if their pre-treatment $K^+$ levels are >5.0 mEq/L   |
|              | A $K^+$ lowering agent should be started.  |
| 4.5-5        | In patients not on maximal guideline-recommended target dose of RAASi therapy, it is recommended to up-titrate/start RAASi therapy and closely monitor $K^+$ levels. |

RAASi, renin angiotensin aldosterone system inhibitor; ARB, angiotensin II receptor blocker; K, potassium; MRA, mineralocorticoid receptor antagonists.

## Current guidelines and management of hyperkalaemia

Current clinical guidelines recommend that patients with chronic hyperkalaemia should be started on a low  $K^+$  diet and have to be initiated on a non- $K^+$  sparing diuretic or if already on a diuretic, to increase the dose.<sup>53-55</sup> All guidelines also suggest to eliminate  $K^+$  supplements and to discontinue drugs that compromise renal function such as NSAIDs and those that may increase  $K^+$  levels such as RAASi therapy, especially MRAs (Table 3).

The ESC Heart Failure Guidelines suggest that if a short-term cessation of  $K^+$ -retaining agents and RAASi is deemed necessary, this should be minimized and RAASi should be carefully reintroduced as soon as possible while monitoring  $K^+$  levels.<sup>20</sup>

As recommended by several regulatory agencies, the chronic use of SPS alone or in conjunction with sorbitol should be avoided because its prolonged use may be associated with severe gastrointestinal side effects such as bowel necrosis.<sup>56</sup> Sodium polystyrene sulfonate has never undergone rigorous testing in placebo-controlled clinical trials to prove its efficacy and safety for treatment of acute or chronic hyperkalaemia.<sup>57,59</sup> In addition, because  $Na^+$  is the counter exchange ion in SPS, caution is advised if it is administered to patients who do not tolerate even a small increase in  $Na^+$  load (i.e. those with HF, severe hypertension, or marked oedema).<sup>59</sup> Here  $K^+$  binders with a different counter exchange ion (i.e. PSC) may be alternatives.

| Patients  | Recommendation  |
|---|---|
| Chronic or recurrent hyperkalaemia on RAASi therapy   | An approved K <sup>+</sup> -lowering agent may be initiated as soon as K <sup>+</sup> levels are confirmed as >5.0 mEq/L. Closely monitor K <sup>+</sup> levels. Maintain treatment unless alternative treatable aetiology is identified  |
| Chronic or recurrent hyperkalaemia not on maximal tolerated guideline-recommended target dose of RAASi                          | RAASi should be optimised and an approved K <sup>+</sup> -lowering agent may be initiated as soon as confirmed K <sup>+</sup> levels are >5.0 mEq/L. Closely monitor K <sup>+</sup> levels. Maintain treatment unless alternative treatable aetiology is identified             |
| K <sup>+</sup> levels of 4.5–5.0 mEq/L not on maximal tolerated, guideline-recommended target dose of RAASi therapy             | Initiate/up-titrate RAASi therapy and closely monitor K <sup>+</sup> levels. If K <sup>+</sup> levels rise above 5.0 mEq/L, initiate an approved K <sup>+</sup> -lowering agent   |
| K <sup>+</sup> levels of >5.0–≤6.5 mEq/L not on maximal tolerated, guideline-recommended target dose of RAASi therapy           | Initiate an approved K <sup>+</sup> -lowering agent. If levels <5.0 mEq/L are detected, up-titrate RAASi - K <sup>+</sup> level should be closely monitored and K <sup>+</sup> lowering treatment should be maintained unless another aetiology for hyperkalaemia is identified |
| K <sup>+</sup> levels of >5.0–≤6.5 mEq/L on maximal tolerated, guideline-recommended target dose of RAASi therapy               | Treatment with a K <sup>+</sup> lowering agent may be initiated. K <sup>+</sup> level should be closely monitored and K <sup>+</sup> lowering treatment should be maintained unless alternative treatable aetiology for hyperkalaemia is identified                             |
| K <sup>+</sup> levels of >6.5 mEq/L on either maximal sub-maximal tolerated, guideline-recommended target dose of RAASi therapy | Discontinue/reduce RAASi. Treatment with a K <sup>+</sup> lowering agent may be initiated as soon as K <sup>+</sup> levels >5.0 mEq/L. K <sup>+</sup> level should be closely monitored   |

**Figure 2** Flow diagram on the management of hyperkalaemia in patients with indication for RAASi therapy.

## Consensus on the implementation of renin angiotensin aldosterone system inhibitors therapies in patients with episodes of hyperkalaemia

Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease but can increase K<sup>+</sup> levels, therapies aimed at lowering K<sup>+</sup> levels and enabling patients to continue RAASi therapy should be considered. Such an approach is already implemented in other fields of medicine, e.g. in cancer where symptomatic therapy is used to enable use of cancer-directed therapy (antiemetics and cytostatic drugs). The use of such an approach in patients with cardiovascular disease, who develop hyperkalaemia or borderline high K<sup>+</sup> level under RAASi therapy may be of benefit to many including those who benefit most from RAASi therapy.

Thus, the recent availability of two new effective and safe K<sup>+</sup> binders, PSC (Veltassa<sup>®</sup>) approved for clinical use in Europe and the USA, and SZC or (ZS-9), approved by European Medicines Agency (EMA) and under final stages of review (at the moment of writing of this manuscript) by United States Food and Drug Administration (US-FDA), are both developed to increase faecal

K<sup>+</sup> excretion mainly in the colon, and open new opportunities for the treatment of hyperkalaemia.<sup>60,61</sup> In clinical trials, both compounds have been shown to be effective to normalize elevated K<sup>+</sup> levels, maintain normo-kalaemia over time and prevent the recurrences of hyperkalaemia in patients with hyperkalaemia on RAASi therapy.<sup>62,68</sup>

Therefore, for most patients with cardiovascular disease and chronic or recurrent hyperkalaemia, RAASi therapy should be optimized whenever possible and treatment with PSC or SZC (when approved) may be initiated. In the absence of clinical guidelines and of *ad hoc* randomized clinical trials with hard endpoints, this consensus is based on inferred available evidence but will need to be confirmed by appropriate clinical trials.<sup>69,70</sup>

In patients with hyperkalaemia an evaluation should be made of the patient's diet, use of supplements, salt substitutes, and nutraceuticals that contain K<sup>+</sup> as well as of concomitant medications that may contribute to hyperkalaemia. Co-administration of drugs known to promote hyperkalaemia or reduce kidney function are not absolute contraindications but should prompt more frequent monitoring of K<sup>+</sup> levels. Kidney function must be determined and monitored. A low-K<sup>+</sup> diet and loop or thiazide diuretics that increase K<sup>+</sup> excretion to reduce the occurrence of hyperkalaemia may be considered. Whenever K<sup>+</sup> lowering therapy is initiated K<sup>+</sup> levels should be closely monitored not only to follow the K<sup>+</sup> lowering effect but also

to protect against development of hypokalaemia, which may be even more dangerous than hyperkalaemia.

In general, RAASi therapy should be started at a low dosage starting an ACEi (ARB when indicated) first and an MRA thereafter and titrated to the maximum tolerated evidence-based doses shown to reduce the risk of cardiovascular and renal events in clinical trials.

In patients with  $K^+$  levels between 4.5 and 5 mEq/L not on maximum tolerated, guideline-recommended target dose of RAASi therapy, it is recommended to titrate/start RAASi therapy and closely monitor  $K^+$  levels. If  $K^+$  levels raise above 5.0 mEq/L,  $K^+$  lowering measures should be initiated.

In patients with as  $K^+$  levels  $>5$  on maximum tolerated, guideline-recommended dose of RAASi therapy, treatment with a  $K^+$  lowering agent may be initiated as soon as  $K^+$  levels  $>5$  mEq/L.  $K^+$  level should be monitored according to the clinical status and  $K^+$  lowering treatment should be maintained unless another aetiology for hyperkalaemia is identified.

Finally, in patients with  $K^+$  levels  $>5$  mEq/L not on maximum tolerated, guideline-recommended target dose of RAASi, therapy with  $K^+$  lowering agents should also be initiated and when  $K^+$  levels are  $<5$  mEq/L titration of RAASi therapy should be implemented. Thereafter,  $K^+$  levels and renal function should be closely monitored and drug dose adjusted (Figure 2).

## Conclusion

This consensus document is based on the available evidence and on expert opinion on the beneficial effect of RAASi therapies in patients with cardiovascular disease. The use of the new  $K^+$  lowering agents may be of help in optimising RAASi therapies in patients with hyperkalaemia or at increased risk of developing it. However, the benefit of  $K^+$  lowering agents enabling and optimizing RAASi therapies on long-term outcomes should be further evaluated in randomized clinical trials.

**Conflict of interest:** Dr. Drexel reports other from Sanofi, other from Amgen, other from Boehringer Ingelheim, other from MSD, other from Bayer, other from NovoNordisk, other from Servier, outside the submitted work. ML has received honoraria from Relypsa and Vifor Pharma. Prof Lund reports grants and consulting from Vifor Pharma, Relypsa and AstraZeneca related to the present work; and grants and consulting from Novartis, consulting from Merck, grants and consulting from Boehringer Ingelheim, and consulting from Sanofi, outside the submitted work. Prof Coats has over the last 3 years received lecture or consultancy fees from: Astra-Zeneca, Respicardia, Resmed, Servier, Vifor, Verona, Actimed, Faraday and Impulse Dynamics. Dr Lainscak has received honoraria from Relypsa and Vifor Pharma. Dr. Anker reports personal fees from Bayer, personal fees from Boehringer Ingelheim, grants and personal fees from Vifor, grants from Abbott Vascular, personal fees from Novartis, personal fees from Servier, personal fees from Stealth, outside the submitted work. Dr. KASKI reports personal fees from SERVIER, personal fees from SANOFI, personal fees from TEVA, personal fees from MENARINI FARMACEUTICA, outside the submitted work. Prof Filippatos participated in committees of trials and registries sponsored by Bayer, Cardioentis, Medtronic, Novartis, Servier,

and Vifor. J.G.F.C. has received research grants from Amgen, Novartis, Stealth BioTherapeutics, and personal fees from Novartis, Stealth BioTherapeutics, and Servier. Prof Piotr Ponikowski has received research grants from Respicardia and Coridea and personal fees from Respicardia, Coridea, and Philips Respiration GK, reports personal fees from Vifor Pharma and AMGEN, and he is consultant for Novartis and Boehringer Ingelheim, outside the submitted work.

## References

1. Poole-Wilson PA. Potassium and the heart. *Clin Endocrinol Metab* 1984;**13**: 249–268.
2. Mathialahan T, MacLennan KA, Sandle LN, Verbeke C, Sandle GI. Enhanced large intestinal potassium permeability in end-stage renal disease. *J Pathol* 2005;**206**: 46–51.
3. Tamargo J, Caballero R, Delpón E. New drugs for the treatment of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors—hype or hope? *Discov Med* 2014;**18**:249–254.
4. Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. *Fundam Clin Pharmacol* 2010;**24**:595–605.
5. Perazella MA. Drug-induced hyperkalaemia: old culprits and new offenders. *Am J Med* 2000;**109**:307–314.
6. Ditttrich KL, Walls RM. Hyperkalaemia: eCG manifestations and clinical considerations. *J Emerg Med* 1986;**4**:449–445.
7. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalaemia. *Am J Emerg Med* 2000;**18**:721.
8. Rastegar A, Soleimani M, Rastegar A. Hypokalaemia and hyperkalaemia. *Postgrad Med J* 2001;**77**:759–764.
9. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalaemia and its significance in chronic kidney disease. *Arch Intern Med* 2009;**169**:1156–1162.
10. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalaemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. *Circ Heart Fail* 2014;**7**:573–579.
11. Ingelfinger JR. A new era for the treatment of hyperkalaemia? *N Engl J Med* 2015; **372**:275–277.
12. Pitt B, Ferreira JP, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. *Eur Heart J* 2017; **3**:48–57.
13. Eschaliel R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalaemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). *J Am Coll Cardiol* 2013;**62**:1585–1593.
14. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD. RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). *J Am Coll Cardiol* 2012;**60**:2082–2089.
15. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013;**34**:2159–2219.
16. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Diab Vasc Dis Res* 2014;**11**:133–173.
17. UK Renal Association. Clinical Practice Guidelines: Treatment of Acute Hyperkalaemia in Adults. <http://www.renal.org/guidelines/joint-guidelines/treatment-of-acute-hyperkalaemia-in-adults-stash.G1GDFeb.dpbs>.
18. National Institute for Health and Care Excellence (NICE). Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care [CG182]. National Institute for Health and Care Excellence. <http://www.nice.org.uk/guidance/cg182>.
19. Alfonzo A, Soar J, MacTier R, Fox J, Shillday I, Nolan J, Kishen R, Douglas A, Bartlett B, Wiese M, Wilson B, Beatson J, Allen A, Goolam M, Whittle M. Clinical practical guidelines. Treatment of acute hyperkalaemia in adults. <http://www.renal.org/docs/default-source/default-document-library/hyperkalaemia-guide-line-march-2014.pdf> (1 September 2017).

20. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
21. An J, Lee J, Jeon H, Kim D, Oh Y, Kim Y, Lim C. Severe hyperkalaemia requiring hospitalization: predictors of mortality. *Crit Care* 2012;**16**:R225.
22. Khanagavi J, Gupta T, Aronow WS, Shah T, Garg J, Ahn C, Sule S, Peterson S. Hyperkalaemia among hospitalized patients and association between duration of hyperkalaemia and outcomes. *Arch Med Sci* 2014;**10**:251–257.
23. Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, Matsushita K, Ballew SH, Coresh J, Grams ME. Antihypertensive medications and the prevalence of hyperkalaemia in a large health system. *Hypertension* 2016;**67**:1181–1188.
24. Takaichi K, Takemoto F, Ubara Y, Mori Y. Analysis of factors causing hyperkalaemia. *Intern Med* 2007;**46**:823–829.
25. Chen Y, Chang AR, McAdams DeMarco MA, Inker LA, Matsushita K, Ballew SH, Coresh J, Grams ME. Serum potassium, mortality, and kidney outcomes in the atherosclerosis risk in communities study. *Mayo Clin Proc* 2016;**91**:1403–1412.
26. Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. *Clin J Am Soc Nephrol* 2016;**11**:90–100.
27. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalaemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. *Arch Intern Med* 1998;**158**:917–924.
28. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalaemia and death in patients with cardiac and renal disease. *Am J Cardiol* 2012;**109**:1510–1513.
29. Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. *BMJ* 2010;**340**:c1768.
30. McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow G, Goyal A, Herzog CA, Kosiborod M, Palmer BF. Acute and chronic cardiovascular effects of hyperkalaemia: new insights into prevention and clinical management. *Rev Cardiovasc Med* 2014;**15**:11–23.
31. Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. *Clin J Am Soc Nephrol* 2010;**5**:531–538.
32. Palmer BF. Managing hyperkalaemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004;**351**:585–592.
33. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K. Prevalence and factors associated with hyperkalaemia in predialysis patients followed in a low-clearance clinic. *Clin J Am Soc Nephrol* 2012;**7**:1234–1241.
34. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. *JAMA* 2015;**314**:1973–1975.
35. Weisberg LS. Management of severe hyperkalaemia. *Crit Care Med* 2008;**36**:3246–3251.
36. Elliott MJ, Ronsley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalaemia. *CMAJ* 2010;**182**:1631–1635.
37. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care* 2015;**21**:S212–S220.
38. Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHEUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) sub-study. *J Am Coll Cardiol* 2011;**58**:1958–1966.
39. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Giererd N, Bakris G, Pitt B, Zannad F. Incidence, determinants, and prognostic significance of hyperkalaemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). *Circ Heart Fail* 2014;**7**:51–58.
40. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;**34**:2949–3003.
41. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;**341**:709–717.
42. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA; CHARM Program Investigators. Incidence and predictors of hyperkalaemia in patients with heart failure: an analysis of the CHARM Program. *J Am Coll Cardiol* 2007;**50**:1959–1966.
43. Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, Benton W, Golestaneh L. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care* 2016;**22**:s311–s324.
44. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associate with hyperkalaemia in patients with congestive heart failure. *J Clin Pharm Therapeutics* 2005;**30**:233–239.
45. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. *J Am Coll Cardiol* 2005;**46**:845–849.
46. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. *J Am Coll Cardiol* 2003;**41**:211–214.
47. Raebel MA. Hyperkalaemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. *Cardiovasc Ther* 2012;**30**:e156–e166.
48. Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozd J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavolunisa A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12440 patients of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2013;**15**:1173–1184.
49. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovsdy CP. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. *J Am Coll Cardiol* 2014;**63**:650–658.
50. Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. *Eur J Heart Fail* 2018;doi: 10.1002/ehf.1079.
51. Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L. QUALIFY Investigators. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. *Eur J Heart Fail* 2016;**18**:514–522.
52. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, Dahlström U. Association between enrolment in a heart failure quality registry and subsequent mortality - a nationwide cohort study. *Eur J Heart Fail* 2017;**19**:1107–1116.
53. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 2004;**43**:11–S290.
54. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. ECC Committee, Subcommittees and Task Forces of the American Heart Association. *Circulation* 2005;**112**:iv1–203.
55. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int* 2013;**3**:S1–S150.
56. Sodium Polystyrene Sulfonate SmPc at MHRA <http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1446186729199.pdf>.
57. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalaemia: are they safe and effective? *J Am Soc Nephrol* 2010;**21**:733–735.
58. Kamel KS, Schreiber M. Asking the question again: are cation exchange resins effective for the treatment of hyperkalaemia? *Nephrol Dial Transplant* 2012;**27**:4294–4297.
59. Kayexalate (sodium polystyrene) [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; revised December 2010. US Food and Drug Administration website. [http://www.accessdata.fda.gov/drugsatfda\\_docs/Label/2011/011287s0231bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/Label/2011/011287s0231bl.pdf).
60. Epstein M, Pitt B. Recent advances in pharmacological treatments of hyperkalaemia: focus on patiromer. *Expert Opin Pharmacother* 2016;**17**:1435–1448.
61. Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalaemia. *Expert Opin Drug Metab Toxicol* 2016;**12**:567–573.
62. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasis Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalaemia on renin-angiotensin system inhibitors. *Kidney Int* 2016;**90**:696–704.



63. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalaemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. *JAMA* 2015;**314**: 151–161.
64. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalaemia receiving RAAS inhibitors. *N Engl J Med* 2015;**372**:211–221.
65. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF trial). *Eur Heart J* 2011;**32**:820–828.
66. Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. *Eur J Heart Fail* 2015;**17**:1050–1056.
67. Tamargo J, Caballero R, Delpón E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. *Cardiovasc Drugs Ther* 2018;**32**:99–119.
68. Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M; Patiromer-204 Investigators. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. *ESC Heart Fail* 2018;doi:10.1002/ehf2.12265.
69. Kjeldsen KP, Tamargo J, Schmidt TA. Potassium binders. In J Camm, et al. eds. *European Society of Cardiology Textbook of Cardiovascular Medicine*. Oxford University Press 2018.
70. Pitt B, Ferreira JP, Zannad F. Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. *Eur Heart J Cardiovasc Pharmacother* 2017;**3**:48–57.